Ozanimod for relapsing-remitting multiple sclerosis

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To assess the efficacy, safety, and tolerability of ozanimod for people with RRMS.

This is a protocol.

Published:

21 April 2022

Authors:

Zhang J, Shi S, Zhang Y, Luo J, Tang J, Luo J

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Zhang J, ShiS, ZhangY, LuoJ, TangJ, LuoJ.Ozanimod for relapsing-remitting multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2021, Issue 2. Art. No.: CD013869. DOI: 10.1002/14651858.CD013869.